Enroll the first patient in the CEDAR clinical trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Nov 2021
- Due
- 31 Dec 2021
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the company remains on track to enroll the first patient in the trial before the end of the year”
What we found
Evidence strength A What the grades mean
The company failed to enroll the first patient by the end of 2021, subsequently announcing in March 2022 that the dosing of the first patient was delayed to the second half of 2022.
-
A LENZ Therapeutics, Inc. 10-Q filed 2022-11-09
“the treatment of the first patient in our Phase 1/2 CEDAR clinical trial was delayed due to a prospective participant becoming infected with COVID-19.” ✓ confirmed on the page
-
A LENZ Therapeutics, Inc. 8-K filed 2022-03-21
“dosing of first patient now planned for second half of 2022” ✓ confirmed on the page
Market reaction: the shares moved -30.5% against the S&P 500 over the three sessions around the disclosure (18 Mar 2022 to 23 Mar 2022). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 10 Nov 2021
Deadline 31 Dec 2021 (“before the end of the year”) · wording firm
-
Version 2 · stated 21 Mar 2022
Deadline 31 Dec 2022 (“second half of 2022”) · wording expected
“the company now plans to dose its first patient in the second half of 2022”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Enroll
- Deliverable
- First patient enrollment in CEDAR trial
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-LENZ-003340 · Corrections policy